目的研究百会穴久留针法通过脑源性神经营养因子(BDNF)/酪氨酸受体激酶B(TrkB)通路改善缺血性脑卒中小鼠神经功能的作用及机制。方法选择雄性C57BL/6J小鼠48只,随机分为假手术1组、模型1组、久留针1组、普通留针组,每组12只。后3组采用...目的研究百会穴久留针法通过脑源性神经营养因子(BDNF)/酪氨酸受体激酶B(TrkB)通路改善缺血性脑卒中小鼠神经功能的作用及机制。方法选择雄性C57BL/6J小鼠48只,随机分为假手术1组、模型1组、久留针1组、普通留针组,每组12只。后3组采用线栓法制备缺血性脑卒中模型,手术造模后第1天起久留针1组和普通留针组分别给予百会穴久留针和普通留针治疗,连续14 d。另选择雄性C57BL/6J小鼠40只,随机分为假手术2组、模型2组、久留针2组、久留针3组,每组10只。后3组采用线栓法制备缺血性脑卒中模型,针灸治疗前分别给予腺相关病毒100μl单次尾静脉注射。采用改良神经功能缺损评分(mNSS)及水迷宫实验的逃避潜伏期、目标象限停留时间、穿越原平台次数评价神经功能。结果与假手术1组比较,模型1组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织BDNF、TrkB表达明显降低,细胞凋亡率及裂解型半胱氨酸天冬氨酸蛋白酶3(Caspase-3)表达明显增加,差异有统计学意义(P<0.05);与模型1组比较,久留针1组和普通留针组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织BDNF、TrkB表达明显增加,细胞凋亡率及裂解型Caspase-3表达明显降低,且久留针1组上述变化较普通留针组更为显著,差异有统计学意义(P<0.05)。与久留针2组比较,久留针3组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织中BDNF表达明显降低(P<0.05),细胞凋亡率及裂解型Caspase-3表达明显增加[(16.41±2.25)%vs(7.59±1.09)%;1.46±0.16 vs 0.94±0.12,P<0.05]。结论百会穴久留针治疗对缺血性脑卒中小鼠神经功能的改善作用更为显著,激活BDNF/TrkB通路是其发挥神经保护作用的相关分子机制。展开更多
动脉性肺动脉高压(Pulmonary Arterial Hypertension, PAH),即第1大类肺动脉高压,是一种以高发病率和死亡率为特点的血管疾病,其主要表现是肺血管重塑和肺血管阻力增加,最终导致右心室衰竭甚至死亡。骨形态发生蛋白9 (Bone Morphogeneti...动脉性肺动脉高压(Pulmonary Arterial Hypertension, PAH),即第1大类肺动脉高压,是一种以高发病率和死亡率为特点的血管疾病,其主要表现是肺血管重塑和肺血管阻力增加,最终导致右心室衰竭甚至死亡。骨形态发生蛋白9 (Bone Morphogenetic Protein 9, BMP9)属于转化生长因子β (Transforming Growth Factor-β, TGF-β)家族,主要由肝脏星状细胞产生,随血液循环到肺血管内皮细胞上与受体结合,在PAH中发挥相应的生物学效应,但是部分研究结果是相互矛盾的。本文对PAH中BMP9的信号通路及BMP9对肺血管内皮细胞作用的研究和进展进行综述。Arterial pulmonary hypertension (PAH), also known as the group 1 pulmonary hypertension, is a vascular disease characterized by high morbidity and mortality, and its main manifestations are pulmonary vascular remodeling and increased pulmonary vascular resistance, which eventually leads to right ventricular failure and even death. Bone Morphogenetic Protein 9 (BMP9) belongs to the Transforming Growth Factor-β (TGF-β) family, which is mainly produced by hepatic stellate cells, which circulates to pulmonary vascular endothelial cells with blood and bind to their receptors to exert corresponding biological effects in PAH, but some research results are contradictory. This article briefly reviews the BMP9 signaling pathway in PAH and the research and progress of BMP9 on pulmonary vascular endothelial cells.展开更多
文摘目的研究百会穴久留针法通过脑源性神经营养因子(BDNF)/酪氨酸受体激酶B(TrkB)通路改善缺血性脑卒中小鼠神经功能的作用及机制。方法选择雄性C57BL/6J小鼠48只,随机分为假手术1组、模型1组、久留针1组、普通留针组,每组12只。后3组采用线栓法制备缺血性脑卒中模型,手术造模后第1天起久留针1组和普通留针组分别给予百会穴久留针和普通留针治疗,连续14 d。另选择雄性C57BL/6J小鼠40只,随机分为假手术2组、模型2组、久留针2组、久留针3组,每组10只。后3组采用线栓法制备缺血性脑卒中模型,针灸治疗前分别给予腺相关病毒100μl单次尾静脉注射。采用改良神经功能缺损评分(mNSS)及水迷宫实验的逃避潜伏期、目标象限停留时间、穿越原平台次数评价神经功能。结果与假手术1组比较,模型1组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织BDNF、TrkB表达明显降低,细胞凋亡率及裂解型半胱氨酸天冬氨酸蛋白酶3(Caspase-3)表达明显增加,差异有统计学意义(P<0.05);与模型1组比较,久留针1组和普通留针组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织BDNF、TrkB表达明显增加,细胞凋亡率及裂解型Caspase-3表达明显降低,且久留针1组上述变化较普通留针组更为显著,差异有统计学意义(P<0.05)。与久留针2组比较,久留针3组mNSS评分、目标象限停留时间、穿越原平台次数及缺血脑组织中BDNF表达明显降低(P<0.05),细胞凋亡率及裂解型Caspase-3表达明显增加[(16.41±2.25)%vs(7.59±1.09)%;1.46±0.16 vs 0.94±0.12,P<0.05]。结论百会穴久留针治疗对缺血性脑卒中小鼠神经功能的改善作用更为显著,激活BDNF/TrkB通路是其发挥神经保护作用的相关分子机制。
文摘动脉性肺动脉高压(Pulmonary Arterial Hypertension, PAH),即第1大类肺动脉高压,是一种以高发病率和死亡率为特点的血管疾病,其主要表现是肺血管重塑和肺血管阻力增加,最终导致右心室衰竭甚至死亡。骨形态发生蛋白9 (Bone Morphogenetic Protein 9, BMP9)属于转化生长因子β (Transforming Growth Factor-β, TGF-β)家族,主要由肝脏星状细胞产生,随血液循环到肺血管内皮细胞上与受体结合,在PAH中发挥相应的生物学效应,但是部分研究结果是相互矛盾的。本文对PAH中BMP9的信号通路及BMP9对肺血管内皮细胞作用的研究和进展进行综述。Arterial pulmonary hypertension (PAH), also known as the group 1 pulmonary hypertension, is a vascular disease characterized by high morbidity and mortality, and its main manifestations are pulmonary vascular remodeling and increased pulmonary vascular resistance, which eventually leads to right ventricular failure and even death. Bone Morphogenetic Protein 9 (BMP9) belongs to the Transforming Growth Factor-β (TGF-β) family, which is mainly produced by hepatic stellate cells, which circulates to pulmonary vascular endothelial cells with blood and bind to their receptors to exert corresponding biological effects in PAH, but some research results are contradictory. This article briefly reviews the BMP9 signaling pathway in PAH and the research and progress of BMP9 on pulmonary vascular endothelial cells.